Amylyx Pharmaceuticals, Inc. (AMLX)
31.62
-0.47
(-1.46%)
USD |
NASDAQ |
Sep 11, 16:00
31.63
+0.01
(+0.03%)
After-Hours: 20:00
Amylyx Pharmaceuticals Enterprise Value : 3.276B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 3.276B |
| September 10, 2026 | 3.328B |
| September 09, 2026 | 3.363B |
| September 08, 2026 | 3.528B |
| September 04, 2026 | 3.552B |
| September 03, 2026 | 3.537B |
| September 02, 2026 | 3.596B |
| September 01, 2026 | 3.520B |
| August 31, 2026 | 3.513B |
| August 28, 2026 | 3.623B |
| August 27, 2026 | 3.895B |
| August 26, 2026 | 3.884B |
| August 25, 2026 | 3.926B |
| August 24, 2026 | 4.003B |
| August 21, 2026 | 4.060B |
| August 20, 2026 | 4.171B |
| August 19, 2026 | 4.053B |
| August 18, 2026 | 3.665B |
| August 17, 2026 | 2.141B |
| August 14, 2026 | 2.163B |
| August 13, 2026 | 2.258B |
| August 12, 2026 | 2.355B |
| August 11, 2026 | 2.386B |
| August 10, 2026 | 2.279B |
| August 07, 2026 | 2.296B |
| Date | Value |
|---|---|
| August 06, 2026 | 2.448B |
| August 05, 2026 | 2.188B |
| August 04, 2026 | 2.190B |
| August 03, 2026 | 2.001B |
| July 31, 2026 | 2.016B |
| July 30, 2026 | 2.065B |
| July 29, 2026 | 1.952B |
| July 28, 2026 | 1.932B |
| July 27, 2026 | 1.925B |
| July 24, 2026 | 1.805B |
| July 23, 2026 | 1.713B |
| July 22, 2026 | 1.726B |
| July 21, 2026 | 1.815B |
| July 20, 2026 | 1.698B |
| July 17, 2026 | 1.731B |
| July 16, 2026 | 1.650B |
| July 15, 2026 | 1.735B |
| July 14, 2026 | 1.781B |
| July 13, 2026 | 1.693B |
| July 10, 2026 | 1.734B |
| July 09, 2026 | 1.801B |
| July 08, 2026 | 1.746B |
| July 07, 2026 | 1.778B |
| July 06, 2026 | 1.756B |
| July 02, 2026 | 1.789B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pfizer Inc. | 209.77B |
| Eli Lilly & Co. | 1.096T |
| Merck & Co., Inc. | 402.09B |
| EyePoint, Inc. | 201.37M |
| Bristol Myers Squibb Co. | 164.00B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.42M |
| Total Expenses (Quarterly) | 43.42M |
| EPS Diluted (Quarterly) | -0.3905 |
| Earnings Yield | -4.53% |
| Normalized Earnings Yield | -4.531 |